

July 22, 2019

To  The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 <sup>th</sup> Floor, Dalal Street Mumbai – 400001  <b>Code: 540222</b>	To  The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051  <b>Code: LAURUSLABS</b>
--	---

Dear Sirs,

**Sub: Laurus Labs' exclusive distribution partner Rising Pharmaceuticals, launches Pregabalin Capsules in US market**

The Company is pleased to announce the launch of the generic version of Lyrica®, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg) in US market along with its exclusive distribution partner Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company. Rising recently received the final approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA).

A press release to this extent is also attached for your information and records.

Thanking you,

Yours sincerely,  
**For Laurus Labs Limited**

  
**G. Venkateswar Reddy**  
Company Secretary



Encl: a.a.

## LAURUS LABS' EXCLUSIVE DISTRIBUTION PARTNER, RISING PHARMACEUTICALS LAUNCHES PREGABALIN CAPSULES IN US MARKET

**Hyderabad, July 22, 2019, Laurus Labs Ltd. (BSE: 540222, NSE: Lauruslabs, ISIN: INE947Q01010)**

Laurus Labs Limited, a leading research and development driven pharmaceutical company along with its exclusive distribution partner Rising Pharmaceuticals, a Rising Pharma Holdings Inc. company, announce the launch of the generic version of Lyrica®, (pregabalin) Capsules, in all eight commercially available strengths (25 mg, 50 mg, 75 mg, 100 mg, 150 mg, 200 mg, 225 mg, & 300 mg) in US market. Rising recently received the final approval from the U.S. Food and Drug Administration (FDA) for the Abbreviated New Drug Application (ANDA).

Pregabalin Capsules are indicated for management of neuropathic pain associated with diabetic peripheral neuropathy, for the management of postherpetic neuralgia, for adjunctive therapy for the treatment of partial onset seizures in patients 4 years of age and older, for the management of fibromyalgia, and for the management of neuropathic pain associated with spinal cord injury. The product should be taken only as prescribed. Pregabalin Capsules had U.S. sales of approximately \$5,497 million for the 12 months ending March 2019, according to IMS Health.

“Laurus Labs is a fully integrated pharmaceutical company, backed by the state of the art manufacturing facilities in Visakhapatnam, Andhra Pradesh. We are happy to develop and manufacture the Pregabalin capsules for our exclusive distribution partner Rising Pharmaceuticals in US. Currently we have 5 billion units per year capacity which can be expanded to 8 million units per year based on the demand. As we move forward in the FDF segment backed by our strong API manufacturing facilities, with strategic partnerships in place, we will strengthen our portfolio for driving long-term, sustainable growth by leveraging our partnerships and global presence,” said **Dr. Satyanarayana Chava, Founder & CEO , Laurus Labs.**

“The commercialization of Pregabalin Capsules is one of the largest volume launches for the company this year and will provide a cost effective treatment option for people living with debilitating neuropathic pain conditions,” said **Vimal Kavuru, Chief Executive Officer for Rising Pharmaceuticals.**

Rising Pharmaceuticals sells generic prescription products and over-the-counter pharmaceutical products under the Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers.

### **About Laurus Labs Limited**


Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses.

**Corporate Identification No: L24239AP2005PLC047518**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

---

**Pavan Kumar N**  
**Laurus Labs Ltd.**  
**Tel:** +91 40 3980 4380  
**Email:** [mediarelations@lauruslabs.com](mailto:mediarelations@lauruslabs.com)

A handwritten signature in blue ink, appearing to read "Alsele".

---

**DISCLAIMER:** Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.